A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge

Abstract Enterovirus 71 (EV71) is an aetiological agent responsible for seasonal epidemics of hand-foot-and-mouth disease, which causes considerable mortality among young children. Mucosal vaccines can efficiently induce secretory IgA at mucosal surfaces and thereby prevent or limit infection at the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Li Lin, Yen-Hung Chow, Li-Min Huang, Szu-Min Hsieh, Pei-Yun Cheng, Kai-Chieh Hu, Bor-Luen Chiang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/69cf232c02d7459f8003b94ae0bbb033
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69cf232c02d7459f8003b94ae0bbb033
record_format	dspace
spelling	oai:doaj.org-article:69cf232c02d7459f8003b94ae0bbb0332021-12-02T15:08:40ZA CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge10.1038/s41598-018-28281-52045-2322https://doaj.org/article/69cf232c02d7459f8003b94ae0bbb0332018-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-28281-5https://doaj.org/toc/2045-2322Abstract Enterovirus 71 (EV71) is an aetiological agent responsible for seasonal epidemics of hand-foot-and-mouth disease, which causes considerable mortality among young children. Mucosal vaccines can efficiently induce secretory IgA at mucosal surfaces and thereby prevent or limit infection at the site of virus entry. CpG oligodeoxynucleotides (ODNs), which resemble bacterial DNA, can induce the innate immune response through activation of Toll-like receptor 9. Here, we used CpG ODNs as adjuvants to investigate an EV71 mucosal vaccine in mice. In the EV71 + CpG group, the EV71-specific IgG and IgA titres in the serum, nasal wash, bronchoalveolar lavage fluid, and faeces were substantially higher than those in the EV71- and phosphate-buffered saline-treated groups. Moreover, the number of EV71-specific IgG- and IgA-producing cells was also higher in the EV71 + CpG group. Furthermore, T-cell proliferative responses and interleukin-17 secretion were markedly increased when CpG-adjuvanted EV71 was delivered intranasally. More importantly, the induced antibodies neutralised infection by EV71 of the C2 genotype and crossneutralised infection by EV71 of the B4 and B5 genotypes. Lastly, human scavenger receptor class B, member 2-transgenic mice intranasally immunised with the CpG-adjuvanted EV71 vaccine resisted a subsequent lethal challenge with EV71, indicating that CpG was an effective intranasal adjuvant for EV71 mucosal-vaccine development.Yu-Li LinYen-Hung ChowLi-Min HuangSzu-Min HsiehPei-Yun ChengKai-Chieh HuBor-Luen ChiangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu-Li Lin Yen-Hung Chow Li-Min Huang Szu-Min Hsieh Pei-Yun Cheng Kai-Chieh Hu Bor-Luen Chiang A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
description	Abstract Enterovirus 71 (EV71) is an aetiological agent responsible for seasonal epidemics of hand-foot-and-mouth disease, which causes considerable mortality among young children. Mucosal vaccines can efficiently induce secretory IgA at mucosal surfaces and thereby prevent or limit infection at the site of virus entry. CpG oligodeoxynucleotides (ODNs), which resemble bacterial DNA, can induce the innate immune response through activation of Toll-like receptor 9. Here, we used CpG ODNs as adjuvants to investigate an EV71 mucosal vaccine in mice. In the EV71 + CpG group, the EV71-specific IgG and IgA titres in the serum, nasal wash, bronchoalveolar lavage fluid, and faeces were substantially higher than those in the EV71- and phosphate-buffered saline-treated groups. Moreover, the number of EV71-specific IgG- and IgA-producing cells was also higher in the EV71 + CpG group. Furthermore, T-cell proliferative responses and interleukin-17 secretion were markedly increased when CpG-adjuvanted EV71 was delivered intranasally. More importantly, the induced antibodies neutralised infection by EV71 of the C2 genotype and crossneutralised infection by EV71 of the B4 and B5 genotypes. Lastly, human scavenger receptor class B, member 2-transgenic mice intranasally immunised with the CpG-adjuvanted EV71 vaccine resisted a subsequent lethal challenge with EV71, indicating that CpG was an effective intranasal adjuvant for EV71 mucosal-vaccine development.
format	article
author	Yu-Li Lin Yen-Hung Chow Li-Min Huang Szu-Min Hsieh Pei-Yun Cheng Kai-Chieh Hu Bor-Luen Chiang
author_facet	Yu-Li Lin Yen-Hung Chow Li-Min Huang Szu-Min Hsieh Pei-Yun Cheng Kai-Chieh Hu Bor-Luen Chiang
author_sort	Yu-Li Lin
title	A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
title_short	A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
title_full	A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
title_fullStr	A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
title_full_unstemmed	A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
title_sort	cpg-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human scarb2-transgenic mice against lethal challenge
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/69cf232c02d7459f8003b94ae0bbb033
work_keys_str_mv	AT yulilin acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT yenhungchow acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT liminhuang acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT szuminhsieh acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT peiyuncheng acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT kaichiehhu acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT borluenchiang acpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT yulilin cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT yenhungchow cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT liminhuang cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT szuminhsieh cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT peiyuncheng cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT kaichiehhu cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge AT borluenchiang cpgadjuvantedintranasalenterovirus71vaccineelicitsmucosalandsystemicimmuneresponsesandprotectshumanscarb2transgenicmiceagainstlethalchallenge
_version_	1718388063654117376

A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge

Ejemplares similares